Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line

International Journal of Cancer

Volumn 68, Issue 1, 1996, Pages 67-74

  Fajac, Anne ^a,b   Da Silva, Jacqueline ^a   Ahomadegbe, Jean Charles ^a   Rateau, Jean Gabriel ^b   Bernaudin, Jean François ^b   Riou, Guy ^a   Bénard, Jean ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CISPLATIN; DNA FRAGMENTATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, P53; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-DIRECTED DNA POLYMERASE; TUMOR CELLS, CULTURED;

EID: 0029982901     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3     Document Type: Article

References (25)

1. AHOMADEGBE, J.C., BARROIS, M., FOGEL, S., LE BIHAN, M.L., DOUCRASY, S., DUVILLARD, P., ARMAND, J.P. and RIOU, G., High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene, 10, 1217-1227 (1995).
2. ANDREWS, P.A. and HOWELL, S.B., Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43 (1990).
3. BECK, D.J. and BRUBAKER. R.R., Mutagenic properties of cis-platinum (II). Mutation Res., 27, 181-189 (1975).
4. BÉNARD, J., DA SILVA, J., DE BLOIS, M.C., BOYER, P., DUVILLARD, P., CHIRIC, E. and RIOU, G., Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res., 45, 4970-4979 (1985).
5. BROWN, R., CLUGSTON, C., BURNS, P., EDLIN, A., VASEY, P., VOJTESEK, B. and KAYE, S.B., Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55, 678-684 (1993).
6. EASTMAN, A., Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2, 275-280 (1990).
7. EVANS, D.L., TILBIE, M. and DIVE, C., Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res., 54, 1596-1603 (1994).
8. FAN, S., EL-DEIRY, W.S., BAE, I., FREEMAN, J., JONDLE, D., BHATIA, K., FORNACE, A.J., JR., MAGRATH, I., KOHN, K.W. and O'CONNOR, P.M., p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54, 5824-5830 (1994).
9. FLAMAN, J.M. and 13 OTHERS, A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. nat. Acad. Sci. (Wash.), 92, 3963-3967 (1995).
10. FUJII, R.I., MUTOH, M., NIWA, K., YAMADA, K., AIKOU, T., NAKAGAWA, M., KUWANO, M. and AKIYAMA, S.I., Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn. J. Cancer Res., 85, 426-433 (1994).
11. HERRMANN, M., LORENTZ, H.M., VOLL, R., GRUNKE, M., WOITH, W. and KALDEN, J.R., A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res., 22, 5506-5507 (1994).
12. KASTAN, M.B., ONYEKWERE, O., SIDRANSKI, D., VOGELSTEIN, B. and CRAIG, R.W., Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311 (1991).
13. KAWAI, K., KAMATANI, N., GEORGES, E. and LING, V., Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J. biol. Chem., 265, 13137-13142 (1990).
14. KONDO, S., BARNETT, G.H., HARA, H., MORIMURA, T. and TAKEUCHI, J., MDM-2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogens, 10, 2001-2006 (1995).
15. LANE, D.P., p53, guardian of the genome. Nature (Lond.), 358, 15-16 (1992).
16. LOWE, S.W., RULEY, H.E., JACKS, T. and HOUSMAN, D.E., p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
17. MASSAAD, L., DE WAZIERS, I., RIBRAG, V., JANOT, F., BEAUNE, P.H., MORIZET, J., GOUYETTE, A. and CHABOT, G.G., Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res., 52, 6567-6575 (1992).
18. MCLAUGHLIN, K., COREN, G., MASTERS, J. and BROWN, R., Binding activities of cis-platin-damage-recognition proteins in human tumor cell lines. Int. J. Cancer, 53, 662-666 (1993).
19. MOMAND, J., ZAMBETTI, G.P., OLSON, D.C., GEORGE, D. and LEVINE, A.J., The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245 (1992).
20. SEGAL-BENDIRDJIAN, E. and JACOUEMIN-SABLON, A., Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp. Cell Res., 218, 201-212 (1995).
21. SMETS, L.A., Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-Cancer Drugs, 5, 3-9 (1994).
22. 2 phase and cell death induced by cisplatin. J. nat. Cancer Inst., 82, 749-755 (1990).
23. VERMORKEN, J.B., VAN DER VIJGH, W.J.F., KLEIN, I., GALL, H.E. and PINEDO, H.M., Pharmacokinetics of free platinum species following a rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Europ. J. Cancer clin. Oncol., 18, 1069-1074 (1982).
24. VIKHANSKAYA, F., ERBA, E., D'INCALCI, M. and MASSIMO, B., Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res., 22, 1012-1017 (1994).
25. WYLLIE, A.M., Apoptosis. Brit. J. Cancer, 67, 205-208 (1993).